I think there is a lot of Monday-morning quarterbacking going on here on this issue. How many people would believe that doctors would withhold access to a proven life-extending drug because of cash flow issues at their practice? Remember, these urologists could simply refer these patients to a larger practice or an academic center and they could get treated. Instead, they are just sitting on them.
Prostate cancer is way more complicated than it appears. I've been ear-deep in this sector for over a decade now and I learn new things about the disease -- not so much scientifically, but how it is treated -- every year.
Despite being one of the bigger killers of men, it is not very well understood by doctors. With no survival-extending therapy until chemo in 2004, docs just aren't used to treating these patients. Add to that a relatively unique split treatment system where uros handle the surgery and oncs handle late-stage disease, you have a boatload of moving parts that make the sector daunting for someone who doesn't spend a **lot** of time on it.
Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr
